Danopharm Chemicals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 2.00 Cr
as on 17-07-2024
- Company Age 15 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 21.18 Cr
as on 17-07-2024
- Satisfied Charges ₹ 11.25 Cr
as on 17-07-2024
- Revenue 5.67%
(FY 2023)
- Profit -36.83%
(FY 2023)
- Ebitda -24.68%
(FY 2023)
- Net Worth 16.26%
(FY 2023)
- Total Assets -1.65%
(FY 2023)
About Danopharm Chemicals
The Corporate was formerly known as Danopharm Chemicals Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹21.18 Cr. The company has closed loans amounting to ₹11.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Satish Nachane, Bimlesh Das, Mehul Nachane, and Five other members serve as directors at the Company.
- CIN/LLPIN
U24100MH2009PTC189592
- Company No.
189592
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jan 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Danopharm Chemicals Private Limited offer?
Danopharm Chemicals Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, API Intermediate.
Who are the key members and board of directors at Danopharm Chemicals?
Board Members(8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mehul Nachane  | Director | 03-Sep-2009 | Current |
| Satish Nachane | Director | 03-Sep-2009 | Current |
| Bimlesh Das | Director | 15-Jan-2009 | Current |
| Ramesh Jadhav | Director | 16-Mar-2010 | Current |
| Sabu Daniel | Director | 16-Mar-2010 | Current |
| Jayanta Das | Director | 15-Jan-2009 | Current |
Financial Performance and Corporate Structure Insights of Danopharm Chemicals.
Danopharm Chemicals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.67% increase. The company also saw a substantial fall in profitability, with a 36.83% decrease in profit. The company's net worth Soared by an impressive increase of 16.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Danopharm Chemicals?
In 2023, Danopharm Chemicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Synergy Health Sciences Private LimitedActive 17 years 3 monthsSatish Nachane, Mehul Nachane and 2 more are mutual person
- Synergy Invesco Private LimitedActive 15 years 2 months
Satish Nachane and Mehul Nachane are mutual person
Sdg Labs Private LimitedActive 11 years 11 monthsSatish Nachane and Mehul Nachane are mutual person
- Rightvalue Research And Investments Private LimitedActive 3 years 1 month
Mehul Nachane is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 21 Jul 2011 | ₹21.18 Cr | Open |
United Bank Of India Creation Date: 15 Sep 2009 | ₹11.25 Cr | Satisfied |
How Many Employees Work at Danopharm Chemicals?
Danopharm Chemicals has a workforce of 85 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Danopharm Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Danopharm Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
